TKT and breast carcinoma: Previous studies on somatic mutations in the TK domain of the her2 gene, in human breast cancer patients, revealed several mutations associated with therapy resistance to TKi and/or specific clinicopathological features, reported in National Cancer Institute database, International Cancer Genome Consortium and COSMIC databases.